ZyVersa Therapeutics Ownership 2024 | Who Owns ZyVersa Therapeutics Now?
Institutional Ownership
1.57%
Insider Ownership
0.61%
Retail Ownership
97.82%
Institutional Holders
6.00
ZyVersa Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
GOLDMAN SACHS GROUP INC | 1.15% | - | 103,471 | 39,213 | 61.02% | 199,699,000 | Mar 31, 2023 |
VANGUARD GROUP INC | 0.19% | - | 16,894 | 16,894 | 100.00% | 32,605,000 | Mar 31, 2023 |
WINTHROP ADVISORY GROUP LLC | 0.15% | 0.00% | 13,361 | 13,361 | 100.00% | 26,000 | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.05% | 0.00% | 4,663 | 4,663 | 100.00% | 9,000 | Mar 31, 2023 |
UBS GROUP AG | 0.04% | - | 3,282 | 3,282 | 100.00% | 6,334,000 | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | 0.00% | - | 28 | 28 | 100.00% | 54,000 | Mar 31, 2023 |
CSS LLC/IL | - | - | - | -14,648 | -100.00% | - | Mar 31, 2023 |
ZyVersa Therapeutics's largest institutional shareholder is GOLDMAN SACHS GROUP INC, holding 1.15% of the company's total share outstanding, currently valued at $199.70M. The top 10 institutional shareholders own together 1.57% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
WINTHROP ADVISORY GROUP LLC | 0.15% | 0.00% | 13,361 | 13,361 | 100.00% | 26,000 | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.05% | 0.00% | 4,663 | 4,663 | 100.00% | 9,000 | Mar 31, 2023 |
GOLDMAN SACHS GROUP INC | 1.15% | - | 103,471 | 39,213 | 61.02% | 199,699,000 | Mar 31, 2023 |
UBS GROUP AG | 0.04% | - | 3,282 | 3,282 | 100.00% | 6,334,000 | Mar 31, 2023 |
VANGUARD GROUP INC | 0.19% | - | 16,894 | 16,894 | 100.00% | 32,605,000 | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | 0.00% | - | 28 | 28 | 100.00% | 54,000 | Mar 31, 2023 |
CSS LLC/IL | - | - | - | -14,648 | -100.00% | - | Mar 31, 2023 |
The largest ZyVersa Therapeutics shareholder by % of total assets is WINTHROP ADVISORY GROUP LLC. The company owns 13.36K shares of ZyVersa Therapeutics (ZVSA), representing 0.00% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
GOLDMAN SACHS GROUP INC | 1.15% | - | 103,471 | 39,213 | 61.02% | 199,699,000 | Mar 31, 2023 |
VANGUARD GROUP INC | 0.19% | - | 16,894 | 16,894 | 100.00% | 32,605,000 | Mar 31, 2023 |
WINTHROP ADVISORY GROUP LLC | 0.15% | 0.00% | 13,361 | 13,361 | 100.00% | 26,000 | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.05% | 0.00% | 4,663 | 4,663 | 100.00% | 9,000 | Mar 31, 2023 |
UBS GROUP AG | 0.04% | - | 3,282 | 3,282 | 100.00% | 6,334,000 | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | 0.00% | - | 28 | 28 | 100.00% | 54,000 | Mar 31, 2023 |
CSS LLC/IL | - | - | - | -14,648 | -100.00% | - | Mar 31, 2023 |
As of Mar 31 2023, ZyVersa Therapeutics's largest institutional buyer is GOLDMAN SACHS GROUP INC. The company purchased 39.21K stocks of ZVSA, valued at $199.70M.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
CSS LLC/IL | - | - | - | -14,648 | -100.00% | - | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | 0.00% | - | 28 | 28 | 100.00% | 54,000 | Mar 31, 2023 |
UBS GROUP AG | 0.04% | - | 3,282 | 3,282 | 100.00% | 6,334,000 | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.05% | 0.00% | 4,663 | 4,663 | 100.00% | 9,000 | Mar 31, 2023 |
WINTHROP ADVISORY GROUP LLC | 0.15% | 0.00% | 13,361 | 13,361 | 100.00% | 26,000 | Mar 31, 2023 |
VANGUARD GROUP INC | 0.19% | - | 16,894 | 16,894 | 100.00% | 32,605,000 | Mar 31, 2023 |
GOLDMAN SACHS GROUP INC | 1.15% | - | 103,471 | 39,213 | 61.02% | 199,699,000 | Mar 31, 2023 |
As of Mar 31 2023, ZyVersa Therapeutics's biggest institutional seller is CSS LLC/IL. The company sold -14.65K shares of ZVSA, valued at -.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
VANGUARD GROUP INC | 0.19% | - | 16,894 | 16,894 | 100.00% | 32,605,000 | Mar 31, 2023 |
WINTHROP ADVISORY GROUP LLC | 0.15% | 0.00% | 13,361 | 13,361 | 100.00% | 26,000 | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.05% | 0.00% | 4,663 | 4,663 | 100.00% | 9,000 | Mar 31, 2023 |
UBS GROUP AG | 0.04% | - | 3,282 | 3,282 | 100.00% | 6,334,000 | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | 0.00% | - | 28 | 28 | 100.00% | 54,000 | Mar 31, 2023 |
ZyVersa Therapeutics's largest new institutional shareholder by number of shares is VANGUARD GROUP INC, purchased 16.89K shares, valued at $32.60M, as of undefined.
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
CSS LLC/IL | - | - | - | -14,648 | -100.00% | - | Mar 31, 2023 |
ZyVersa Therapeutics's largest sold out institutional shareholder by shares sold is CSS LLC/IL, sold -14.65K shares, valued at -, as of undefined.
ZyVersa Therapeutics Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
FIDELITY CONCORD STREET TRUST | 0.00% | 123,130 | - | - | Feb 29, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 17,194 | - | - | Mar 31, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 3,520 | 3,520 | - | Feb 29, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 493 | -493 | -50.00% | Mar 31, 2024 |
ZyVersa Therapeutics's largest mutual fund holder by % of total assets is "FIDELITY CONCORD STREET TRUST", owning 123.13K shares, compromising 0.00% of its total assets.
ZyVersa Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
31 Mar, 23 | 6 | 200.00% |
31 Dec, 22 | 2 | - |
As of 31 Mar 23, 6 institutions are holding ZyVersa Therapeutics's shares, representing an increase of 200.00% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
31 Mar, 23 | 141,699 | 79.58% |
31 Dec, 22 | 78,906 | - |
ZyVersa Therapeutics (ZVSA) has 141.70K shares outstanding as of 31 Mar 23, up 79.58% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
31 Mar, 23 | 1.57% | - |
31 Dec, 22 | - | - |
As of 31 Mar 23, ZyVersa Therapeutics is held by 1.57% institutional shareholders, representing a 0.00% growth compared to 31 Dec 22.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
31 Mar, 23 | 1 | - |
31 Dec, 22 | - | - |
1 institutional shareholders have increased their position in ZVSA stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
31 Mar, 23 | - | - |
31 Dec, 22 | - | - |
- institutional shareholders have reduced their position in ZVSA stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar, 23 | 6 | 200.00% | 141,699 | 79.58% | 1.57% | - | 1 | - | - | - |
31 Dec, 22 | 2 | - | 78,906 | - | - | - | - | - | - | - |
ZyVersa Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
Open Market Insider Buys
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
Insider Sells
All Insider Owners Trades
The last insider sell of ZyVersa Therapeutics's stock was made by Guzman Pablo A. on Jan 26 2023, selling 9,015 shares at $6.90 per share (valued at $62.20K).
ZyVersa Therapeutics Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q1 2023 | 1 | 1 | 100.00% |
Q4 2022 | - | 1 | - |
Q1 2022 | 7 | 6 | 116.67% |
1 total buy trades, and 1 total sell trades (buy/sell ratio of 1.00%) were made by ZyVersa Therapeutics's insiders, as of Q1 2023.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q1 2023 | - | - | - |
Q4 2022 | - | - | - |
Q1 2022 | - | - | - |
As of Q1 2023, Insider owners conducted 0 open market buy trades and 0 open market sell trades of ZyVersa Therapeutics's stocks.
ZVSA Ownership FAQ
Who Owns ZyVersa Therapeutics?
ZyVersa Therapeutics is owned by institutional shareholders (1.57%), insiders (0.61%), and public (97.82%). The largest institutional shareholder of ZyVersa Therapeutics is GOLDMAN SACHS GROUP INC (1.15% of total shares) and the top mutual fund owner is FIDELITY CONCORD STREET TRUST (0.00% of total shares).
Who are the major institutional shareholders of ZyVersa Therapeutics?
ZyVersa Therapeutics's major institutional shareholders are GOLDMAN SACHS GROUP INC, VANGUARD GROUP INC, WINTHROP ADVISORY GROUP LLC, TOWER RESEARCH CAPITAL LLC (TRC), and UBS GROUP AG. The top five shareholders own together 1.57% of the company's share outstanding.
How many ZyVersa Therapeutics shareholders are there?
As of Mar 2023, there are 6 institutional shareholders of ZyVersa Therapeutics.
What percentage of ZyVersa Therapeutics is owned by GOLDMAN SACHS GROUP INC?
GOLDMAN SACHS GROUP INC owns 103.47K shares of ZyVersa Therapeutics, representing 1.15% of the company's total shares outstanding, valued at $199.7M (as of Mar 2023).
What percentage of ZyVersa Therapeutics is owned by VANGUARD GROUP INC?
As of Mar 2023, VANGUARD GROUP INC holds 16.89K shares of ZyVersa Therapeutics (ZVSA), compromising 0.19% of the company, valued at $32.6M.
What percentage of ZyVersa Therapeutics is owned by WINTHROP ADVISORY GROUP LLC?
WINTHROP ADVISORY GROUP LLC is the third largest holder of ZyVersa Therapeutics. The company owns 13.36K of the company's shares outstanding (worth $26K).